According to data released by LSEG Deals Intelligence, the healthcare sector saw a 35% increase on last year’s deals, reaching $174.6 billion in the first half of 2023 – a
Australian radiopharma developer Telix Pharma and US neuroscience specialist Rapport Therapeutics have become the latest biotechs to weigh in for initial public offerings
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.